CTLA4 and cancer: These antibodies target molecules like cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1), and programmed death ligand 1 (PD-L1), ushering in a new era in the treatment of various types of cancers [9].